Please sign in to follow a disease.
Changchun Genescience Pharmaceutical Co., Ltd.
Clinical trials sponsored by Changchun Genescience Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New bacterial vaginosis drug passes first safety check in healthy volunteers Results expected Sep 2026 (estimated)
- New pill could tame phenylketonuria by blocking amino acid absorption Results expected Sep 2026 (estimated)
- New injection for Graves' disease enters first human tests Results expected Oct 2026 (estimated)
- Head-to-Head: which drug tames high prolactin better? Results expected Nov 2026 (estimated)
- New growth hormone drug enters first human tests Results expected Nov 2026 (estimated)
-
Experimental drug gentulizumab tested for tough blood cancers – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis Stopped earlyThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC